drugset / Trial / NCT05310331
Donafenib for Recurrent Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the safety and tolerability of Donafenib combined with paclitaxel and platinum ± programmed death 1 monoclonal antibody (PD-1 antibody) in patients with recurrent cervical cancer.
Timeline
- Start
- 2022-03-27
- Primary completion
- 2023-12-27
- Completion
- 2024-06-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cisplatin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Donafenib | Small molecule | 200 mg | Oral |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |